Are cannabinoids effective in multiple sclerosis?

Meza, Rodrigo; Peña, Javier; García, Karen; Corsi, Oscar; Rada, Gabriel

doi:10.5867/medwave.2017.6865

Cited by 9 publications

(9 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Limited literature regarding previous systematic reviews and meta-analysis was found. 6 , 7 , 8 , 9 , 10 , 11 The results from these studies were relatively incomplete.…”

Section: Introductionmentioning

confidence: 99%

Assessment of Efficacy and Tolerability of Medicinal Cannabinoids in Patients With Multiple Sclerosis

et al. 2018

View full text Add to dashboard Cite

Key Points Question Are medicinal cannabinoids effective and well tolerated in the treatment of multiple sclerosis? Findings In this systematic review and meta-analysis of 17 randomized clinical trials including 3161 patients, cannabinoids were significantly associated with efficacy for subjective spasticity, pain, and bladder dysfunction compared with placebo. Cannabinoids had a higher risk of adverse events and withdrawals due to adverse events, with no statistically significant differences found for serious adverse events. Meaning Cannabinoids appear to be safe regarding serious adverse events, but their clinical benefit may be limited.

show abstract

“…Limited literature regarding previous systematic reviews and meta-analysis was found. 6 , 7 , 8 , 9 , 10 , 11 The results from these studies were relatively incomplete.…”

Section: Introductionmentioning

confidence: 99%

Assessment of Efficacy and Tolerability of Medicinal Cannabinoids in Patients With Multiple Sclerosis

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Dizziness/lightheadedness (14–59%), gastrointestinal symptoms (diarrhea, nausea, and vomiting) (13–37% in active groups), dry mouth (4–26% in active groups), urinary tract infections (15.4–34%), and other adverse effects, such as fatigue, headache, attention disturbance, and disorientation, are the most commonly reported adverse effects in MS patients treated with cannabinoids [ 56 , 57 , 77 , 112 ]. A recent study tookadvantage of The Epistemonikos database, and analyzed 25 systematic reviews on the use of cannabinoids in MS patients; they concluded that the benefit–risk ratio of using cannabinoids in these patients is unfavorable, because there is a high level of evidence about the lack of benefits, and adverse effects are common [ 114 ]. The majority of assessments of these studies found no evidence that any of these side effects limit clinical use [ 72 ].…”

Section: Adverse Effectsmentioning

confidence: 99%

The Efficacy of Cannabis on Multiple Sclerosis-Related Symptoms

Haddad

Dokmak

2022

Life

View full text Add to dashboard Cite

Multiple sclerosis (MS) is known as an autoimmune disease that damages the neurons in the central nervous system. MS is characterized by its most common symptoms of spasticity, muscle spasms, neuropathic pain, tremors, bladder dysfunction, dysarthria, and some intellectual problems, including memory disturbances. Several clinical studies have been conducted to investigate the effects of cannabis on the relief of these symptoms in MS patients. The efficacy of Cannabis sativa (C. Sativa) in the management of MS outcomes such as spasticity, pain, tremors, ataxia, bladder functions, sleep, quality of life, and adverse effects were assessed in this review. Most clinical studies showed the positive effects of cannabinoids with their different routes of administration, such as oromucosal spray and oral form, in reducing most MS symptoms. The oromucosal spray Nabiximols demonstrated an improvement in reducing MS spasticity, pain, and quality of life with a tolerated adverse effect. Oral cannabinoids are significantly effective for treating MS pain and spasticity, while the other symptoms indicate slight improvement and the evidence is quite inconsistent. Oromucosal spray and oral cannabis are mainly used for treating patients with MS and have positive effects on treating the most common symptoms of MS, such as pain and spasticity, whereas the other MS symptoms indicated slight improvement, for which further studies are needed.

show abstract

“…is increasing. [7][8][9] However, clinical practice guideline recommendations and evidence from published literature are varied and/or inconclusive. 1 Rehabilitation professionals manage various MS-related symptoms and provide information to patients (and families) about the potential benefit and harm from cannabinoid usage for symptomatic treatment of MS.…”

Section: What Are the Implications Of The Cochrane Evidence For Pract...mentioning

confidence: 99%

“…The use of cannabinoid-based medicines to alleviate MS-related symptoms (such as spasticity, pain, etc.) is increasing 7–9 . However, clinical practice guideline recommendations and evidence from published literature are varied and/or inconclusive 1 .…”

Section: Introductionmentioning

confidence: 99%

Are Cannabis and Cannabinoids Effective for Symptomatic Treatment in People With Multiple Sclerosis?

Amatya

Khan

2022

Am J Phys Med Rehabil

View full text Add to dashboard Cite

see www.cochranelibrary.com for information). Cochrane Reviews are regularly updated as new evidence emerges and in response to feedback, and Cochrane Database of Systematic Reviews should be consulted for the most recent version of the review. The views expressed in the summary with commentary are those of the Cochrane Corner author(s) (different than the original Cochrane Review authors) and do not represent the Cochrane Library or Wiley.

show abstract

Are cannabinoids effective in multiple sclerosis?

Cited by 9 publications

References 0 publications

Assessment of Efficacy and Tolerability of Medicinal Cannabinoids in Patients With Multiple Sclerosis

Assessment of Efficacy and Tolerability of Medicinal Cannabinoids in Patients With Multiple Sclerosis

The Efficacy of Cannabis on Multiple Sclerosis-Related Symptoms

Are Cannabis and Cannabinoids Effective for Symptomatic Treatment in People With Multiple Sclerosis?

Contact Info

Product

Resources

About